451 related articles for article (PubMed ID: 25434768)
1. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies.
Bollineni VR; Koole MJ; Pruim J; Brouwer CL; Wiegman EM; Groen HJ; Vlasman R; Halmos GB; Oosting SF; Langendijk JA; Widder J; Steenbakkers RJ
Radiother Oncol; 2014 Nov; 113(2):198-203. PubMed ID: 25434768
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: a planning study.
Servagi-Vernat S; Differding S; Sterpin E; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V
Acta Oncol; 2015 Jul; 54(7):1008-16. PubMed ID: 25562382
[TBL] [Abstract][Full Text] [Related]
3. A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy.
Servagi-Vernat S; Differding S; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1544-52. PubMed ID: 24570097
[TBL] [Abstract][Full Text] [Related]
4. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial.
Mortensen LS; Johansen J; Kallehauge J; Primdahl H; Busk M; Lassen P; Alsner J; Sørensen BS; Toustrup K; Jakobsen S; Petersen J; Petersen H; Theil J; Nordsmark M; Overgaard J
Radiother Oncol; 2012 Oct; 105(1):14-20. PubMed ID: 23083497
[TBL] [Abstract][Full Text] [Related]
5. Imaging of hypoxia with 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy.
Trinkaus ME; Blum R; Rischin D; Callahan J; Bressel M; Segard T; Roselt P; Eu P; Binns D; MacManus MP; Ball D; Hicks RJ
J Med Imaging Radiat Oncol; 2013 Aug; 57(4):475-81. PubMed ID: 23870348
[TBL] [Abstract][Full Text] [Related]
6. PET imaging of tumor hypoxia using 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients.
Bollineni VR; Kerner GS; Pruim J; Steenbakkers RJ; Wiegman EM; Koole MJ; de Groot EH; Willemsen AT; Luurtsema G; Widder J; Groen HJ; Langendijk JA
J Nucl Med; 2013 Aug; 54(8):1175-80. PubMed ID: 23753185
[TBL] [Abstract][Full Text] [Related]
7. Influence of FAZA PET hypoxia and HPV-status for the outcome of head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy: Long-term results from the DAHANCA 24 trial (NCT01017224).
Saksø M; Mortensen LS; Primdahl H; Johansen J; Kallehauge J; Hansen CR; Overgaard J
Radiother Oncol; 2020 Oct; 151():126-133. PubMed ID: 32805273
[TBL] [Abstract][Full Text] [Related]
8. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2-nitroimidazole ( 18F-FAZA).
Postema EJ; McEwan AJ; Riauka TA; Kumar P; Richmond DA; Abrams DN; Wiebe LI
Eur J Nucl Med Mol Imaging; 2009 Oct; 36(10):1565-73. PubMed ID: 19430784
[TBL] [Abstract][Full Text] [Related]
9. Assessment of hypoxic subvolumes in laryngeal cancer with (18)F-fluoroazomycinarabinoside ((18)F-FAZA)-PET/CT scanning and immunohistochemistry.
Bruine de Bruin L; Bollineni VR; Wachters JE; Schuuring E; van Hemel BM; van der Wal JE; Slagter-Menkema L; de Bock GH; Steenbakkers RJ; Langendijk JA; Pruim J; van der Laan BF; Halmos GB
Radiother Oncol; 2015 Oct; 117(1):106-12. PubMed ID: 26250803
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer.
Grosu AL; Souvatzoglou M; Röper B; Dobritz M; Wiedenmann N; Jacob V; Wester HJ; Reischl G; Machulla HJ; Schwaiger M; Molls M; Piert M
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):541-51. PubMed ID: 17869667
[TBL] [Abstract][Full Text] [Related]
11. Correlation analysis of [
Di Perri D; Lee JA; Bol A; Hanin FX; Janssens G; Labar D; Robert A; Sterpin E; Geets X
Acta Oncol; 2017 Sep; 56(9):1181-1188. PubMed ID: 28537761
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of PET/CT with (18)F-fluoroazomycin arabinoside for patients with head and neck squamous cell carcinomas receiving chemoradiotherapy.
Saga T; Inubushi M; Koizumi M; Yoshikawa K; Zhang MR; Obata T; Tanimoto K; Harada R; Uno T; Fujibayashi Y
Ann Nucl Med; 2016 Apr; 30(3):217-24. PubMed ID: 26662072
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 trial of bevacizumab with concurrent chemoradiation therapy for squamous cell carcinoma of the head and neck with exploratory functional imaging of tumor hypoxia, proliferation, and perfusion.
Nyflot MJ; Kruser TJ; Traynor AM; Khuntia D; Yang DT; Hartig GK; McCulloch TM; Wiederholt PA; Gentry LR; Hoang T; Jeraj R; Harari PM
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):942-51. PubMed ID: 25659884
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
Kinoshita T; Fujii H; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H
Lung Cancer; 2016 Jan; 91():56-66. PubMed ID: 26711935
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia PET Tracers in EBRT Dose Planning in Head and Neck Cancer.
Hodolič M; Fettich J; Kairemo K
Curr Radiopharm; 2015; 8(1):32-7. PubMed ID: 25808959
[TBL] [Abstract][Full Text] [Related]
16. 18F-FAZA PET/CT in the Preoperative Evaluation of NSCLC: Comparison with 18F-FDG and Immunohistochemistry.
Mapelli P; Bettinardi V; Fallanca F; Incerti E; Compierchio A; Rossetti F; Coliva A; Savi A; Doglioni C; Negri G; Gianolli L; Picchio M
Curr Radiopharm; 2018; 11(1):50-57. PubMed ID: 29119942
[TBL] [Abstract][Full Text] [Related]
17. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study.
Souvatzoglou M; Grosu AL; Röper B; Krause BJ; Beck R; Reischl G; Picchio M; Machulla HJ; Wester HJ; Piert M
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1566-75. PubMed ID: 17447061
[TBL] [Abstract][Full Text] [Related]
18. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
[TBL] [Abstract][Full Text] [Related]
19. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of (18) F-fluoroazomycin arabinoside PET/CT in patients with advanced non-small-cell lung cancer.
Saga T; Inubushi M; Koizumi M; Yoshikawa K; Zhang MR; Tanimoto K; Horiike A; Yanagitani N; Ohyanagi F; Nishio M
Cancer Sci; 2015 Nov; 106(11):1554-60. PubMed ID: 26292100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
